| Title |
Pharmacological effects of Ro 22-1319: A new antipsychotic agent
|
|---|---|
| Published in |
Psychopharmacology, January 1983
|
| DOI | 10.1007/bf00433013 |
| Pubmed ID | |
| Authors |
Arnold B. Davidson, Edward Boff, Donald A. MacNeil, James Wenger, Leonard Cook |
| Abstract |
Ro 22-1319, a novel pyrroloisoquinoline compound, was identified as a potential antipsychotic agent in a rat discrete avoidance procedure that is highly specific for such agents. Results in this test are highly correlated with the clinical potency of all types of antipsychotic agents. The avoidance-blocking potency of Ro 22-1319 (0.7 mg/kg) in this procedure approached that of haloperidol (0.4 mg/kg) and was 7- and 12-times greater than that of chlorpromazine and clozapine, respectively. Ro 22-1319 exhibited similar high potency in other rat and monkey avoidance procedures, rat motor activity, and antagonism of apomorphine emesis in dogs. High potency and antipsychotic-like activity have been demonstrated in monkey EEG and in an in vivo 3H-spiroperidol binding assay. Although studies of amphetamine antagonism in rats indicate antidopaminergic activity at nigrostriatal sites, Ro 22-1319 exhibited relatively weaker cataleptogenic and antistereotypic activity than haloperidol, and had minimal activity in a rat chronic stereotypy model of receptor supersensitivity. This profile suggests that Ro 22-1319 is an efficacious antipsychotic compound, almost as potent as haloperidol, with fewer or less intense extrapyramidal effects and low potential for tardive dyskinesia. |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 50% |
| Student > Doctoral Student | 1 | 13% |
| Other | 1 | 13% |
| Student > Ph. D. Student | 1 | 13% |
| Researcher | 1 | 13% |
| Other | 0 | 0% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 4 | 50% |
| Agricultural and Biological Sciences | 1 | 13% |
| Biochemistry, Genetics and Molecular Biology | 1 | 13% |
| Medicine and Dentistry | 1 | 13% |
| Neuroscience | 1 | 13% |
| Other | 0 | 0% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2014.
All research outputs
#7,454,427
of 22,789,566 outputs
Outputs from Psychopharmacology
#2,099
of 5,346 outputs
Outputs of similar age
#5,904
of 33,366 outputs
Outputs of similar age from Psychopharmacology
#5
of 15 outputs
Altmetric has tracked 22,789,566 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,346 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 33,366 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.